BioCentury
ARTICLE | Company News

Sequenom, GlaxoSmithKline deal

January 22, 2001 8:00 AM UTC

SQNM will validate 500 SNPs and screen them against more than 900 DNA samples, all provided by GSK, from patients with Type II diabetes and controls using its MassARRAY technology and automated assay ...